Praxis Precision Medicines (PRAX) said Friday it received a recommendation from an independent data monitoring committee overseeing its study 1 of the so-called Essential3 program of ulixacaltamide in essential tremor that the trial be "stopped for futility."
Truist Securities adjusted Praxis's share-price target to $85 from $175 while maintaining its buy rating.
Shares of Praxis slumped 39% following a surge in intraday trading volume to over 2.1 million from a daily average of about 363,000.
DoubleVerify (DV) reported a surprise drop late Thursday in Q4 net income, and its guidance range for Q1 sales also missed market expectations.
Goldman Sachs downgraded the company's shares to neutral from buy, with a $20 price target.
Shares of DoubleVerify sank 36%, with intraday trading volume catapulting to over 10 million versus a daily average of about 1.5 million.
NetApp (NTAP) "unexpectedly stumbled" in fiscal Q3 with revenue at the low end of guidance, and Q4 rebound expectations "muted," Wedbush Securities said Friday in a review of NetApp's earnings overnight.
Wells Fargo adjusted NetApp's share-price target to $115 from $130 while keeping its equal-weight rating.
Shares of NetApp retreated 17% as intraday trading volume surged to more than 5.5 million from a daily average of roughly 1.6 million.
Price: 39.70, Change: -25.33, Percent Change: -38.95
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.